Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
EBIATLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsReceivables RefundsShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Ratios

Gsk (GLAXF) Short-Term Debt repayments (2016 - 2025)

Historic Short-Term Debt repayments for Gsk (GLAXF) over the last 17 years, with Q4 2025 value amounting to -$99.8 million.

  • Gsk's Short-Term Debt repayments fell 13438.9% to -$99.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$317.8 million, marking a year-over-year decrease of 42411.56%. This contributed to the annual value of -$317.8 million for FY2025, which is 1001.21% down from last year.
  • According to the latest figures from Q4 2025, Gsk's Short-Term Debt repayments is -$99.8 million, which was down 13438.9% from -$75.5 million recorded in Q3 2025.
  • Gsk's Short-Term Debt repayments' 5-year high stood at $6.0 billion during Q4 2022, with a 5-year trough of -$3.8 billion in Q2 2022.
  • For the 5-year period, Gsk's Short-Term Debt repayments averaged around -$141.8 million, with its median value being -$73.9 million (2024).
  • Examining YoY changes over the last 5 years, Gsk's Short-Term Debt repayments showed a top increase of 135425.53% in 2022 and a maximum decrease of 89256.78% in 2022.
  • Gsk's Short-Term Debt repayments (Quarter) stood at -$474.5 million in 2021, then soared by 1354.26% to $6.0 billion in 2022, then tumbled by 95.89% to $244.5 million in 2023, then grew by 18.64% to $290.1 million in 2024, then crashed by 134.39% to -$99.8 million in 2025.
  • Its Short-Term Debt repayments stands at -$99.8 million for Q4 2025, versus -$75.5 million for Q3 2025 and -$70.7 million for Q2 2025.